NewsBenzingaGyre Therapeutics reafirma una previsión de ventas para el ejercicio fiscal 2026 de 100,500 millones de dólares a 111,000 millones de dólares, frente a una estimación de 109,500 millones de dólares. Gyre Therapeutics reafirma una previsión de ventas para el ejercicio fiscal 2026 de 100,500 millones de dólares a 111,000 millones de dólares, frente a una estimación de 109,500 millones de dólares. Benzinga 2026.11.05 22:30 (GMT+0) Open on Benzinga Other news Ardent Health Stock Tumbles 14.61% After Hours: Here's Why Lowe's Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Elon Musk Had a Facepalm Moment After Sean Duffy Defends Rejecting Free Starlink for FAA: ‘Our Airspace Is Very Big’ Abdul El-Sayed Tells Trump He Has Chance to ‘Heal the Sick’: Senator-Elect Says ‘People Really Want Health Care’ Reported Earlier, SPAC Berto To Combine With AMPERA At About $900M Pre-Money Equity Value; Up To $357M Gross Cash Proceeds Expected Iridex (NASDAQ: IRIX) Shares Fall 26.96% After Hours: What Investors Should Know
Lowe's Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Elon Musk Had a Facepalm Moment After Sean Duffy Defends Rejecting Free Starlink for FAA: ‘Our Airspace Is Very Big’
Abdul El-Sayed Tells Trump He Has Chance to ‘Heal the Sick’: Senator-Elect Says ‘People Really Want Health Care’
Reported Earlier, SPAC Berto To Combine With AMPERA At About $900M Pre-Money Equity Value; Up To $357M Gross Cash Proceeds Expected